Disease/Infection News

RSS

Brown, University of Cape Town partner to create next generation of HIV social science in South Africa

The public health schools at Brown University and the University of Cape Town have launched a new research and training partnership to create "the next generation of HIV social science in South Africa." The Eunice Kennedy Shriver National Institute of Child Health and Human Development is funding the collaboration with a new $1.9 million, five-year grant.

10 Sep 2013

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.

9 Sep 2013

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PharmAthene, Inc. announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus – ACT international anthrax conference in Victoria, British Columbia, Canada.

7 Sep 2013

COPDF launches pocket consultant guide iPhone app for effective diagnosis, therapy of COPD

The COPD Foundation (COPDF) announces today the launch of its COPD Pocket Consultant Guide (PCG) iPhone app, a practical tool designed to facilitate easier, more effective diagnosis and therapy for Chronic Obstructive Pulmonary Disease (COPD) during daily clinical care.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Social media and online communities can improve health behaviors among men at risk of HIV

A UCLA study published Sept. 3 in the peer-reviewed journal Annals of Internal Medicine demonstrates that an approach that combines behavioral science with social media and online communities can lead to improved health behaviors among men at risk of HIV infection.

7 Sep 2013

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.

6 Sep 2013

Researchers hope to protect humans from another deadly outbreak like HIV

Throughout Asia, humans and monkeys live side-by side in many urban areas. An international research team from the University of Washington, Fred Hutchinson Cancer Research Center and Jahangirnagar University has been examining transmission of a virus from monkeys to humans in Bangladesh, one of the world's most densely populated countries.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR-) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

4 Sep 2013

Researchers uncover evidence that Richard III had roundworm infection

Researchers based at the University of Cambridge and the University of Leicester have uncovered evidence that Richard III suffered from a roundworm (Ascaris lumbricoides) infection, according to a Clinical Picture published in The Lancet.

4 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013

Large study shows effective test for diagnosis of C-Diff infection

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in the United States.

4 Sep 2013

Iron deficiency anemia may offer protection against malaria infection

Children in a malaria-endemic community in Ghana who received a micronutrient powder with iron did not have an increased incidence of malaria, according to a study in the September 4 issue of JAMA. Previous research has suggested that iron supplementation for children with iron deficiency in malaria-endemic areas may increase the risk of malaria.

4 Sep 2013

Precisely designed macromolecule mimics binding of HIV to immune system cells

A precisely designed macromolecule that mimics the binding of HIV to immune system cells could be used to stop the virus from physically entering the body, according to a new study led by a materials scientist at Queen Mary University of London.

4 Sep 2013

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.

4 Sep 2013

Study shows how stomach bacteria manipulates human immune system to survive in stomach

Helicobacter pylori is a bacterium that establishes a life-long stomach infection in humans, which in some cases can lead to duodenal ulcers or stomach cancer. New research, presented at this week's Society for General Microbiology Autumn Conference, gives us a clearer understanding of how these bacteria can manipulate the human immune system to survive in the mucosal lining of the stomach.

4 Sep 2013

New vaccine to protect against four strains of flu virus

For the first time, there will be a vaccine which protects against four strains of the flu virus. Until now, flu vaccines have only protected against three forms of the virus.

4 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Disease/Infection News

Brown, University of Cape Town partner to create next generation of HIV social science in South Africa

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

COPDF launches pocket consultant guide iPhone app for effective diagnosis, therapy of COPD

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Social media and online communities can improve health behaviors among men at risk of HIV

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers hope to protect humans from another deadly outbreak like HIV

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

Researchers uncover evidence that Richard III had roundworm infection

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

Large study shows effective test for diagnosis of C-Diff infection

Iron deficiency anemia may offer protection against malaria infection

Precisely designed macromolecule mimics binding of HIV to immune system cells

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

Study shows how stomach bacteria manipulates human immune system to survive in stomach

New vaccine to protect against four strains of flu virus

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News